Evaluating the Impact of Clinical Pharmacy Services on Blood Pressure Control in Primary Care: A Quantitative Analysis

Sultan A. Alsubaie[1], Saad M. Aldhafyan[2], Abdullah A. Alahmari[3], Waseem N. Alshahrani[4]

Pharmacist
Health affairs at the Ministry of National Guard

Abstract

Background: Effective management of hypertension in primary care is crucial for reducing cardiovascular risk. Clinical pharmacy services (CPS) have been proposed as a means to improve hypertension control, medication adherence, and overall patient outcomes.

Objective: This study evaluates the impact of CPS on blood pressure control, medication adherence, quality of life, and healthcare utilization among hypertensive patients in primary care settings.

Methods: A quantitative, quasi-experimental design was employed. Patients receiving CPS were compared to a control group using pre- and post-intervention measurements of blood pressure, medication adherence (measured by MMAS-8), quality of life (assessed by EQ-5D), and healthcare utilization (tracked through medical records).

Results: The CPS group demonstrated significant reductions in systolic and diastolic blood pressure, improved medication adherence, and enhanced quality of life compared to the control group. Additionally, the CPS group experienced fewer emergency visits and hospitalizations.

Conclusion: Integrating clinical pharmacy services into primary care settings significantly improves blood pressure control and patient outcomes while reducing healthcare utilization. These findings support the expanded role of pharmacists in managing hypertension.

Keywords: Clinical Pharmacy Services, Hypertension Management, Blood Pressure Control, Medication Adherence, Quality of Life, Healthcare Utilization

Introduction

Hypertension remains a prevalent and critical public health issue worldwide, with significant implications for cardiovascular morbidity and mortality. Effective management of hypertension is essential to reduce the risk of complications such as stroke, myocardial infarction, and chronic kidney disease (Hedegaard et al., 2015). In primary care settings, where the majority of hypertension cases are managed, there is a growing emphasis on enhancing the quality of care through the integration of specialized clinical services.

Clinical pharmacy services have been recognized for their potential to improve medication management and patient outcomes in various healthcare settings. These services, which include medication therapy management, patient education, and interdisciplinary collaboration, have been shown to enhance therapeutic outcomes and optimize medication use (Ramanath et al., 2012). Despite this, the specific impact of clinical pharmacy services on blood pressure control in primary care has not been extensively quantified.

The role of clinical pharmacists in managing hypertension involves conducting comprehensive medication reviews, identifying and addressing drug-related problems, and providing patient counseling to improve adherence and lifestyle modifications (Qudah et al., 2016). Studies have suggested that clinical pharmacy interventions can lead to significant improvements in blood pressure control, but these findings are often based on limited or heterogeneous evidence (Anderson and Schumock, 2009).

This study aims to evaluate the effectiveness of clinical pharmacy services in improving blood pressure control among hypertensive patients in primary care settings. By analyzing data from a primary care clinic

implementing these services, the study will provide insights into how clinical pharmacy interventions contribute to better hypertension management and offer evidence to support the integration of these services into routine primary care practice.

Literature Review

Hypertension Management in Primary Care: Hypertension is a leading risk factor for cardiovascular diseases and remains a major public health challenge. Effective management of hypertension in primary care settings is crucial for reducing the incidence of related complications. According to Hedegaard et al. (2015), the primary objectives in hypertension management include achieving and maintaining target blood pressure levels and minimizing the risk of adverse cardiovascular events. Standard treatment approaches involve lifestyle modifications and pharmacotherapy, which are often managed by primary care physicians (PCPs).

Clinical Pharmacy Services: Clinical pharmacy services encompass a range of activities designed to optimize medication use and improve patient outcomes. These services include medication therapy management (MTM), patient education, and collaborative care with other healthcare professionals (Ramanath et al., 2012). Clinical pharmacists have been integrated into various healthcare settings to address medication-related problems, enhance adherence, and ensure optimal therapeutic outcomes.

Impact of Clinical Pharmacy Services on Hypertension Management: Recent studies highlight the positive impact of clinical pharmacy services on hypertension management. Clinical pharmacists are instrumental in performing comprehensive medication reviews, identifying and addressing drug-related issues, and providing education on lifestyle changes and medication adherence (Qudah et al., 2016). These interventions have been associated with improved blood pressure control, increased medication adherence, and reduced incidence of adverse drug events Anderson and Schumock, 2009).

Evidence Supporting Clinical Pharmacy Interventions: Several studies have demonstrated the effectiveness of clinical pharmacy interventions in managing hypertension. For instance, a study by Ramanath et al. (2012) found that clinical pharmacy services led to significant improvements in blood pressure control among patients with hypertension. The study highlighted that pharmacists' involvement in patient education and medication management contributed to better adherence and more effective treatment outcomes.

Another study by Qudah et al. (2016) assessed a pharmacist-led hypertension management program and reported favorable outcomes, including improved blood pressure readings and enhanced patient satisfaction. The study emphasized the role of pharmacists in providing personalized care and monitoring treatment progress.

Despite these positive findings, some literature suggests that the impact of clinical pharmacy services on hypertension management may vary depending on the specific interventions employed and the context of the primary care setting (Anderson and Schumock, 2009). Variability in study designs, sample sizes, and intervention strategies necessitates a closer examination of how these services can be optimized for different patient populations and clinical environments.

Gaps in Current Research: While existing literature supports the efficacy of clinical pharmacy services in improving hypertension management, there is a need for more rigorous and comprehensive studies to further validate these findings. The majority of studies have been limited by small sample sizes, short study durations, and heterogeneous methodologies (Ramanath et al., 2012). There is also a lack of research examining the long-term impact of clinical pharmacy interventions on hypertension outcomes and healthcare utilization.

The integration of clinical pharmacy services in primary care has shown promise in enhancing hypertension management. However, further research is needed to quantify the impact of these services more precisely and to identify best practices for their implementation. This study aims to address these gaps by evaluating the effectiveness of clinical pharmacy services in improving blood pressure control among hypertensive patients in primary care settings.

Methodology

Study Design: This study utilized a quantitative, prospective cohort design to evaluate the impact of clinical pharmacy services on the management of hypertension in primary care settings. The study was conducted over a period of 12 months.

Setting and Participants: The study was conducted in tertiary hospital. A total of 200 hypertensive patients aged 18 and older, who were prescribed antihypertensive medications, were recruited for the study.

Participants were enrolled based on the following inclusion criteria: (1) diagnosis of hypertension according to (Hedegaard et al., 2015), (2) currently receiving antihypertensive therapy, and (3) willing to provide informed consent. Patients were excluded if they had secondary hypertension or were unable to comply with follow-up appointments.

Intervention : Participants were randomly assigned to either the intervention group or the control group. The intervention group received comprehensive clinical pharmacy services, which included:
1. **Medication Therapy Management (MTM):** Clinical pharmacists conducted detailed medication reviews to identify and resolve drug-related problems.
2. **Patient Education:** Pharmacists provided individualized counseling on hypertension management, medication adherence, and lifestyle modifications.
3. **Follow-Up and Monitoring:** Regular follow-up appointments with the clinical pharmacist were scheduled to monitor blood pressure levels, assess adherence, and adjust therapy as needed.

The control group received standard care from their primary care providers without additional pharmacy services.

Outcome Measures: The primary outcome measure was the change in systolic and diastolic blood pressure from baseline to 12 months, assessed through regular clinic visits and home monitoring. Secondary outcomes included:
1. **Medication Adherence:** Measured using the Morisky Medication Adherence Scale (MMAS-8) (Morisky et al., 2008).
2. **Quality of Life:** Evaluated using the EQ-5D scale (EuroQoL Group, 1990).
3. **Healthcare Utilization:** Recorded through clinic records, including the frequency of emergency visits and hospitalizations.

Data Collection and Analysis: Data were collected at baseline, 6 months, and 12 months. Blood pressure measurements were taken by trained staff using calibrated sphygmomanometers. Medication adherence was assessed through patient self-reports and pharmacy refill records.

Statistical analyses were performed using SPSS version 28.0. Descriptive statistics were used to summarize demographic and baseline characteristics. Changes in blood pressure between the intervention and control groups were analyzed using independent t-tests and analysis of covariance (ANCOVA), adjusting for baseline values. Medication adherence and quality of life outcomes were compared using chi-square tests and t-tests. A p-value of <0.05 was considered statistically significant.

Ethical Considerations: The study was approved by the ethics committee. Informed consent was obtained from all participants prior to enrollment. Confidentiality of patient data was maintained throughout the study.

Findings
Participant Characteristics: A total of 200 participants were enrolled in the study, with 100 individuals in the intervention group and 100 in the control group. Table 1 summarizes the baseline characteristics of the participants.

Table 1: Baseline Characteristics of Participants

Characteristic	Intervention Group (n=100)	Control Group (n=100)	p-value
Age (years)	60.2 ±8.4	59.8 ±8.7	0.652
Gender (Male/Female)	45/55	47/53	0.765
Mean Baseline SBP (mmHg)	148.3 ±12.5	147.9 ±13.0	0.832
Mean Baseline DBP (mmHg)	92.1 ±8.9	91.8 ±9.2	0.875
Comorbidities (n, %)	55 (55%)	53 (53%)	0.793

Blood Pressure Outcomes: Table 2 presents the changes in systolic and diastolic blood pressure from baseline to 12 months for both groups.

Table 2: Changes in Blood Pressure

Measurement	Intervention Group (n=100)	Control Group (n=100)	p-value
Baseline SBP (mmHg)	148.3 ±12.5	147.9 ±13.0	0.832
12-Month SBP (mmHg)	130.5 ±11.2	142.8 ±12.7	<0.001
Baseline DBP (mmHg)	92.1 ±8.9	91.8 ±9.2	0.875
12-Month DBP (mmHg)	81.5 ±7.6	89.3 ±8.4	<0.001

Medication Adherence: Medication adherence was significantly higher in the intervention group compared to the control group, as shown in Table 3.

Table 3: Medication Adherence

Measure	Intervention Group (n=100)	Control Group (n=100)	p-value
MMAS-8 Score (mean ±SD	7.9 ±1.2	6.5 ±1.4	<0.001
Adherent (n, %)	85 (85%)	65 (65%)	0.002

Quality of Life: Table 4 shows the changes in quality of life scores as measured by the EQ-5D scale.

Table 4: Quality of Life Scores

Measurement	Intervention Group (n=100)	Control Group (n=100)	p-value
Baseline EQ-5D Score	0.68 ±0.15	0.66 ±0.14	0.421
12-Month EQ-5D Score	0.82 ±0.12	0.71 ±0.13	<0.001

Healthcare Utilization: Table 5 summarizes the healthcare utilization data, including the number of emergency visits and hospitalizations.

Table 5: Healthcare Utilization

Measure	Intervention Group (n=100)	Control Group (n=100)	p-value
Emergency Visits (mean ±SD)	1.2 ±0.9	2.3 ±1.1	<0.001
Hospitalizations (mean ±SD)	0.4 ±0.5	1.1 ±0.7	<0.001

Discussion

This study assessed the impact of clinical pharmacy services on hypertension management in primary care, focusing on outcomes such as blood pressure control, medication adherence, quality of life, and healthcare utilization. The results demonstrate that clinical pharmacy services are associated with significant improvements in these areas.

Blood Pressure Control: The intervention group showed a significant reduction in both systolic and diastolic blood pressure compared to the control group. This aligns with previous research indicating that clinical pharmacy services, including medication therapy management and patient education, can substantially lower blood pressure (Qudah et al., 2016). Clinical pharmacists often engage in comprehensive medication reviews and adjust therapy based on patient-specific needs, which has been shown to enhance blood pressure control (Bex et al., 2014). The findings from this study reinforce the effectiveness of these strategies in managing hypertension.

Medication Adherence: Improved medication adherence was observed in the intervention group, as reflected by higher scores on the Medication Adherence Scale (MMAS-8). This finding corroborates studies that highlight the positive impact of clinical pharmacists on medication adherence (Hedegaard et al., 2015). Clinical pharmacy services often include adherence counseling and medication synchronization, which contribute to better patient adherence (Saleem et al., 2015). This enhanced adherence is crucial for achieving and maintaining optimal blood pressure control.

Quality of Life: The intervention group experienced improvements in quality of life, as measured by the EQ-5D scale. This result is consistent with research indicating that effective hypertension management through clinical pharmacy services can lead to enhanced quality of life (Ramanath et al., 2012). Better blood pressure control and improved adherence likely contribute to the observed improvements in patient well-being, highlighting the broader benefits of clinical pharmacy interventions beyond just clinical outcomes.

Healthcare Utilization: A reduction in emergency visits and hospitalizations was noted in the intervention group, supporting previous findings that clinical pharmacy services can lower healthcare utilization by improving disease management and preventing complications (Anderson and Schumock, 2009). This reduction is indicative of the potential cost-effectiveness of incorporating clinical pharmacists into primary care teams, as they can help manage chronic conditions more effectively and reduce the need for acute care (Gallagher et al., 2014).

Limitations and Future Research: The study's limitations include its geographic focus and observational design, which may affect the generalizability of the findings. Future research should consider multi-center trials to validate these results across diverse populations. Additionally, longitudinal studies could provide insights into the long-term impact of clinical pharmacy services on hypertension management. Qualitative research exploring patient and provider perspectives could also offer valuable information on the mechanisms behind the improved outcomes observed in this study.

Conclusion

Integrating clinical pharmacy services into primary care significantly enhances blood pressure control, medication adherence, and quality of life while reducing healthcare utilization. These results underscore the value of clinical pharmacists in managing hypertension and suggest that expanding these services could lead to improved patient outcomes and greater healthcare efficiency.

References

1. Anderson, S. V., & Schumock, G. T. (2009). Evaluation and justification of clinical pharmacy services. *Expert review of pharmacoeconomics & outcomes research*, *9*(6), 539-545.
2. Bex, S. D., Boldt, A. S., Needham, S. B., Bolf, S. M., Walston, C. M., Ramsey, D. C., ... & Zillich, A. J. (2011). Effectiveness of a hypertension care management program provided by clinical pharmacists for veterans. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *31*(1), 31-38.
3. Gallagher, J., McCarthy, S., & Byrne, S. (2014). Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. *International journal of clinical pharmacy*, *36*, 1101-1114.

4. Hedegaard, U., Kjeldsen, L. J., Pottegård, A., Henriksen, J. E., Lambrechtsen, J., Hangaard, J., & Hallas, J. (2015). Improving medication adherence in patients with hypertension: a randomized trial. *The American journal of medicine*, *128*(12), 1351-1361.

5. Qudah, B., Albsoul-Younes, A., Alawa, E., & Mehyar, N. (2016). Role of clinical pharmacist in the management of blood pressure in dialysis patients. *International journal of clinical pharmacy*, *38*, 931-940.

6. Ramanath, K. V., Balaji, D. B. S. S., Nagakishore, C. H., Kumar, S. M., & Bhanuprakash, M. (2012). A study on impact of clinical pharmacist interventions on medication adherence and quality of life in rural hypertensive patients. *Journal of Young Pharmacists*, *4*(2), 95-100.

7. Saleem, F., Hassali, M. A., Shafie, A. A., Ul Haq, N., Farooqui, M., Aljadhay, H., & Ahmad, F. U. D. (2015). Pharmacist intervention in improving hypertension-related knowledge, treatment medication adherence and health-related quality of life: a non-clinical randomized controlled trial. *Health Expectations*, *18*(5), 1270-1281.